降压治疗长期心血管获益的个体数据荟萃分析
该研究基于51项随机试验、358,642名参与者的个体数据,分析降压治疗对主要心血管事件(MACE)风险的长期影响。结果显示,收缩压每降低5 mmHg,第1年MACE风险即降低12%(HR=0.88,95%CI 0.84-0.91),此后获益未随时间递增,提示应优先治疗高风险个体。
要点
- 收缩压降低5 mmHg在第1年即显著降低MACE风险(HR=0.88)。
- 降压的相对获益在数年内出现,不随治疗时间延长而增加。
- 优先治疗高心血管风险个体比长期治疗低风险个体更具临床价值。
核心结论
- 降压治疗的心血管相对获益在数月内即出现,且不随治疗时间延长而增加。
- 优先治疗高风险个体比长期治疗低风险个体具有更大的临床效用。
研究设计与样本
- 血压降低治疗试验者协作组(BPLTTC)51项随机试验的个体参与者数据荟萃分析,共358,642名参与者,中位随访4.2年。
- 采用Cox比例风险模型估计按随访年份分层的时间特异性风险比,并以5 mmHg收缩压降幅标准化。
- 采用网络荟萃分析比较不同降压药物类别的时间模式差异。
主要发现
- 年MACE发生率第1年最高(治疗组3.0% vs 对照组3.6%),第1-5年下降,5年以上回升(3.1% vs 3.4%)。
- 收缩压降低5 mmHg第1年MACE风险降低12%(HR=0.88,95%CI 0.84-0.91)。
- 此后获益轻度衰减:第1-2年HR=0.88(0.85-0.92),第2-3年HR=0.94(0.90-0.98),第3-4年HR=0.87(0.83-0.92),第4-5年HR=0.97(0.91-1.03),5年以上HR=0.94(0.87-1.01),趋势P=0.006。
- 五种降压药物类别呈现相似模式。
关键数值与推荐
- MACE定义为致死或非致死性卒中、缺血性心脏病或心力衰竭。
- 以收缩压降低5 mmHg为标准化的主要效应量。
- 51项随机试验,358,642名参与者,中位随访4.2年,趋势检验P=0.006。
临床怎么用
- 降压治疗应尽早启动,不必为追求更大相对获益而延长疗程。
- 资源有限时优先覆盖心血管高风险人群,而非长期治疗低风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blood pressure (BP)-lowering therapy reduces cardiovascular risk, but whether its proportional benefits increase with longer treatment duration remains unclear. We conducted an individual participant-level data meta-analysis of 51 randomized trials from the Blood Pressure Lowering Treatment Trialists' Collaboration (358,642 participants; median follow-up: 4.2 years). Using Cox proportional hazards models, we estimated time-stratified hazard ratios (HRs) for major cardiovascular events (MACE; fatal or non-fatal stroke, ischemic heart disease or heart failure) across annual follow-up intervals up to more than 5 years, standardized to a 5-mmHg systolic BP reduction. Network meta-analysis examined whether temporal patterns differed across antihypertensive drug classes. Annual MACE incidence was highest during year 1 (3.0% treatment versus 3.6% control), declined during years 1-5 and then rose at more than 5 years (3.1% versus 3.4%). BP lowering reduced MACE risk, with benefits established early and not progressively increasing over time. A 5-mmHg systolic BP reduction was associated with a 12% lower MACE risk in year 1 (HR = 0.88, 95% confidence interval (CI): 0.84-0.91), with modest attenuation thereafter: HRs were 0.88 (0.85-0.92) in years 1-2, 0.94 (0.90-0.98) in years 2-3, 0.87 (0.83-0.92) in years 3-4, 0.97 (0.91-1.03) in years 4-5 and 0.94 (0.87-1.01) at more than 5 years (P for trend = 0.006). Similar patterns occurred across five drug classes. These findings indicate that the relative cardiovascular benefits of BP lowering emerge within months and do not increase over time, suggesting that prioritizing higher-risk individuals for treatment yields greater clinical utility than prolonged treatment in low-risk individuals.
引用
- Yang Q, Bidel Z, Canoy D, et al. A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials. Nat Med. 2026. PMID: 42387214. doi:10.1038/s41591-026-04514-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。